Advertisement

Unmet Medical Needs and the Role of Pharmaceutical Companies

  • Wolfgang Meyer-Sabellek
Chapter
  • 435 Downloads
Part of the International Library of Ethics, Law, and the New Medicine book series (LIME, volume 44)

Rising health care costs have been prioritized in the budget planning of all Western countries. Rising R&D costs of up to $800 million per marketed new pharmaceutical have dramatically reduced the approval of new chemical entities (NCEs). Globalization of diseases like AIDS and SARS has had a definite impact on the economic situation not only in the Western world, but also in developing countries, especially for AIDS in Africa and SARS in Asia. The World Health Organization (WHO) is calling for free anti-tuberculosis (TB) drugs to be made available to people living with human immunodeficiency virus (HIV). The spread between unmet medical need in large indications (e.g. Alzheimer's disease) and in niche indications (e.g. Huntington disease) and the economic burden to create a blockbuster ($1 billion sales within one year after launch) has created a marketing-driven clinical development of new chemical entities. A paradigm shift has occurred by which developing a new innovative drug by documenting shortterm efficacy, quality and safety rather than long-term efficacy and emphasizing pharma-covilliglance including considerations of health economy within the medical environment a shift that has fundamentally changed and challenged the pharmaceutical industry.

Keywords

Huntington Disease Conventional Risk Factor Pharmaceutical Benefit Advisory Committee Parallel Trade Male Pattern Baldness 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    R. Roberts, W. Rodriguesz, D. Murphy, T. Crescenzi (2003) Pediatric Drug Labelling.JAMA290: 905–911.PubMedCrossRefGoogle Scholar
  2. 2.
    K.X. Hy, D.M. Keller (2000) Prevalence of AD Among Whites : A Summary by Levels of Severity.Neurology55: 198–204.PubMedGoogle Scholar
  3. 3.
    R.L. Nussbaum, C.E. Ellis (2003) Alzheimer's Disease and Parkinson's Disease.N Engl J Med348 (14): 1356–1364.PubMedCrossRefGoogle Scholar
  4. 4.
    K.M. Venkat Narayan et al. (2003) Lifetime Risk for Diabetes Mellitus in the United States.JAMA290: 1884–1890.CrossRefGoogle Scholar
  5. 5.
    U.N. Khot et al. (2003) Prevalence of Conventional Risk Factors in Patients With Coronary Heart Disease.JAMA290: 898–904.PubMedCrossRefGoogle Scholar
  6. 6.
    D.G. Hackam, S.S. Anand (2003) Emerging Risk Factors for Atherosclerotic Vascular Disease.JAMA290: 932–940.PubMedCrossRefGoogle Scholar
  7. 7.
    M. Hersberger, A. von Eckardstein (2003) Low High-Density Lipoprotein Cholesterol. Physiological Background, Clinical Importance and Drug Treatment.Drugs2003; 63(18):1907–1945.PubMedCrossRefGoogle Scholar
  8. 8.
    Long-term intervention with pravastatin in ischemic disease (LIPID) study group (1998) Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels.N Engl J Med339 (19): 349–357.Google Scholar
  9. 9.
    David Gilbert et al. (2000) Life Style Medicine.BMJ321: 1341–1344.CrossRefGoogle Scholar
  10. 10.
    D. Reissman (1999) The Pros and Cons of Covering Lifestyle Drugs.Dis Manag Health Outcomes6: 249–251.CrossRefGoogle Scholar
  11. 11.
    Australian Department of Health Agency (2002) Guidelines for the Pharmaceutical Industry on Preparation of Submission to the Pharmaceutical Benefits Advisory Committee.Google Scholar
  12. 12.
    J.M. Reichert (2003) Trends in development and approval. times for new therapeutics in the United States.Nature Reviews Drug Discovery2: 695–702.PubMedCrossRefGoogle Scholar
  13. 13.
    J.F. Pritchard et al. (2003) Making better drugs: decision gates in non-clinical drug development.Nature Reviews Drug Discovery2: 542–553.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • Wolfgang Meyer-Sabellek
    • 1
  1. 1.Professor, Institute for Social MedicineEpidemiology and Health Economics, Charité University Medical Centre BerlinGermany

Personalised recommendations